Gland Pharma shares surged over 8% in early morning trade after the company reported a strong set of consolidated results for Q3 FY26, reflecting healthy growth across revenue, operating profit, and net profit on a year-on-year basis.
In its Q3 FY26 earnings, Gland Pharma posted consolidated revenue of Rs 1,695 crore, marking a 22.5% increase compared to Rs 1,384 crore reported in the same quarter last year.
Operating performance also remained robust during the quarter. EBITDA rose 20.8% year-on-year to Rs 435 crore from Rs 360 crore in Q3 FY25. However, EBITDA margin stood at 25.6%, marginally lower than 26% recorded in the corresponding quarter of the previous year.
On the bottom line, Gland Pharma delivered a solid improvement in profitability. Net profit for the quarter increased 27.7% to Rs 262 crore, compared with Rs 205 crore in the same period last year. The stronger profit growth relative to revenue highlights better cost management and operating leverage during the quarter.
Following the announcement of these Q3 FY26 results, market participants reacted positively, with Gland Pharma shares rallying over 8% in early trade.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
